The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions -- all of which led to a sell-off on Aug. 5. It's reasonable for investors to be a bit nervous about committing more of their capital given the volatility and ongoing uncertainty.

Nonetheless, I predict that loading up on a basket of biopharma stocks during this unsteadiness will prove to be a profitable decision in the long run. Here's why.

To start, let's examine the mid-sell-off performance of a few popular biotech and pharma stocks. Recursion Pharmaceuticals (NASDAQ: RXRX), Eli Lilly (NYSE: LLY), Viking Therapeutics (NASDAQ: VKTX), and (NYSE: PFE) are all depicted in the chart below:

Continue reading

Source Fool.com